Last Updated : May 8, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Ralivia | Tramadol hydrochloride | Pain | Do not list | Complete | ||
| RAPAFLO | Silodosin | Benign prostatic hyperplasia | Do not list | Complete | ||
| Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | N/A | Complete | ||
| Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | List with clinical criteria and/or conditions | Complete | ||
| Rasilez | Aliskiren | Hypertension | Do not list | Complete | ||
| Ravicti | glycerol phenylbutyrate | Urea cycle disorders | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rebif | Interferon beta-1a | Clinically isolated syndrome | Do not list | Complete | ||
| Reblozyl | luspatercept | beta-thalassemia associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Reblozyl | luspatercept | Myelodysplastic syndromes-associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Relistor | Methylnaltrexone bromide | Constipation, Opioid-induced | Do not list | Complete |
Last Updated : May 8, 2024